You are here

  • Home
  • Archive
  • Volume 23, Issue Suppl 1
  • CP-207 Analysis of effectiveness and safety of enzalutamide and abiraterone in patients with unresectable prostate adenocarcinoma resistant to castration

Article info

Article menu
Download PDFPDF
Clinical pharmacy
CP-207 Analysis of effectiveness and safety of enzalutamide and abiraterone in patients with unresectable prostate adenocarcinoma resistant to castration

Authors

Citation

Lista FM, Salvador AR, Andújar NL, et al
CP-207 Analysis of effectiveness and safety of enzalutamide and abiraterone in patients with unresectable prostate adenocarcinoma resistant to castration
European Journal of Hospital Pharmacy 2016;23:A91-A92.

Publication history

  • First published February 14, 2016.
Online issue publication 
May 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions